GlycoMimetics has announced that the European Patent Office has issued an "intention to grant" letter for European Patent Application Number EP12813711.1, titled "E-Selectin Antagonist Compounds, Compositions, and Methods of Use."
This patent is part of GlycoMimetics' expanding patent portfolio covering the drug candidate GMI-1271 and its uses in a variety of indications, including various cancers. The US Patent and Trademark Office has already issued a patent covering GMI-1271. GlycoMimetics has ongoing efforts to secure additional US and foreign patents. With the issuance of patents in the US and Europe, GlycoMimetics will have claims directed at GMI-1271 extending at least until 2032.
"The European Patent Office's issuance of patent rights covering GMI-1271 underscores the progress we've made in protecting our intellectual property and innovative pipeline," said Rachel King, Chief Executive Officer, GlycoMimetics. "The release of promising new clinical data in both the newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) patient populations from our ongoing study during the 2017 ASCO and EHA meetings, the U.S. Food and Drug Administration's (FDA) Breakthrough Therapy Designation, and our enhanced patent position provide a strong foundation for defining a pivotal registration program and commercialization strategy for GMI-1271."
Glycomimetics, european patent covering, variety of indications
14.jpg)
